Improving medication adherence in patients with blood cancers and other chronic conditions
Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence
This study is testing if working together with pharmacists can help patients with blood cancers and other chronic conditions take their medications more regularly and manage their symptoms better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Tennessee Academic / other |
| Locations | 1 site (Nashville, Tennessee) |
| Trial ID | NCT04663100 on ClinicalTrials.gov |
What this trial studies
This pilot study aims to enhance the management of medication, symptoms, and diseases in patients with hematological malignancies and multiple chronic conditions through coordinated care between pharmacists in oncology and primary care settings. The study will assess the relationship between patient-reported outcomes and medication adherence, focusing on those initiating or changing oral anticancer agents. Although the sample size is limited, the findings will inform a larger controlled study in the future.
Who should consider this trial
Good fit: Ideal candidates include patients receiving cancer care at Vanderbilt University Medical Center with a diagnosis of chronic lymphocytic leukemia, chronic myeloid leukemia, or multiple myeloma, who also have at least two chronic conditions.
Not a fit: Patients who cannot communicate in English or have concurrent diagnoses of type 1 diabetes or HIV may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve medication adherence and overall health outcomes for patients with blood cancers and multiple chronic conditions.
How similar studies have performed: While this pilot study is novel in its specific approach, similar studies have shown promise in improving medication adherence through coordinated care models.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Receiving cancer care at Vanderbilt University Medical Center * Diagnosis of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), chronic myeloid leukemia (CML), or multiple myeloma (MM) * Initiating an oral anticancer agent, either for the first time or a change from previous oral agent * Diagnosis of 2 chronic conditions, including at least one of the following: diabetes, hypertension, hyperlipidemia, congestive heart failure, depression/anxiety, gastroesophageal reflux disease, and/or chronic obstructive pulmonary disease * Patients taking at least two chronic medications, including at least one medication for one of the conditions listed above. * Willing and able to sign informed consent. Exclusion Criteria: * Cannot communicate in English * Concurrent diagnosis of type 1 diabetes or human immunodeficiency virus
Where this trial is running
Nashville, Tennessee
- Vanderbilt University Medical Center — Nashville, Tennessee, United States (Recruiting)
Study contacts
- Study coordinator: Justin Gatwood, PhD
- Email: jgatwood@uthsc.edu
- Phone: 6155323403
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.